{"id":"angiotensin-ii-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Ischemic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Angiotensin II acts as a potent vasoconstrictor by binding to AT1 and AT2 receptors on vascular smooth muscle and endothelial cells, leading to increased peripheral vascular resistance and blood pressure elevation. It also promotes aldosterone release and sodium retention, further contributing to hemodynamic stabilization. This mechanism is particularly useful in treating distributive shock and severe hypotension where catecholamine-resistant hypotension occurs.","oneSentence":"Angiotensin II is a vasoactive peptide that binds to angiotensin II receptors to increase blood pressure and restore vascular tone in patients with hypotension.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:16.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Distributive shock (septic shock) with hypotension refractory to catecholamines"},{"name":"Severe hypotension in critically ill patients"}]},"trialDetails":[{"nctId":"NCT06272487","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-02-29","conditions":"High Cardiovascular Risk, Hypertension","enrollment":375},{"nctId":"NCT07312292","phase":"PHASE2","title":"Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","status":"NOT_YET_RECRUITING","sponsor":"Niek Wijnen","startDate":"2026-01-01","conditions":"Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult","enrollment":15},{"nctId":"NCT04936035","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-07-07","conditions":"Hypertension","enrollment":394},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT06423352","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-06-05","conditions":"Mild to Moderate Hypertension","enrollment":36},{"nctId":"NCT06282965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2024-05-28","conditions":"Traumatic Brain Injury","enrollment":90},{"nctId":"NCT04714320","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-04-28","conditions":"Hypertension","enrollment":160},{"nctId":"NCT06351150","phase":"PHASE3","title":"Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07-23","conditions":"Vasodilatory Shock","enrollment":214},{"nctId":"NCT05709444","phase":"PHASE2","title":"A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2022-12-26","conditions":"Kidney Disease","enrollment":16},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06013839","phase":"PHASE2","title":"TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy","status":"UNKNOWN","sponsor":"Constant Therapeutics LLC","startDate":"2023-08-31","conditions":"DMD-Associated Dilated Cardiomyopathy","enrollment":10},{"nctId":"NCT06135103","phase":"PHASE2","title":"Phase 2 Study of TXA127 in Post-ischemic Stroke Patients","status":"UNKNOWN","sponsor":"Constant Therapeutics LLC","startDate":"2023-11-26","conditions":"Ischemic Stroke","enrollment":50},{"nctId":"NCT05893108","phase":"PHASE1, PHASE2","title":"Ethosomal Gel Bearing Losartan 5% for Keloid Treatment","status":"UNKNOWN","sponsor":"Yuni Eka Anggraini","startDate":"2024-03-30","conditions":"Keloid","enrollment":46},{"nctId":"NCT04836182","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-06-08","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":72},{"nctId":"NCT04083222","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-11-13","conditions":"Hypertension","enrollment":26},{"nctId":"NCT03714776","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-01-03","conditions":"Mild Hypertension","enrollment":25},{"nctId":"NCT04647552","phase":"","title":"Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock","status":"COMPLETED","sponsor":"Inonu University","startDate":"2020-11-01","conditions":"Shock, Septic","enrollment":40},{"nctId":"NCT03615196","phase":"PHASE1","title":"Study of the Safety of USB005 in Healthy Volunteers","status":"COMPLETED","sponsor":"US Biotest, Inc.","startDate":"2018-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01882374","phase":"PHASE2","title":"Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation","status":"WITHDRAWN","sponsor":"Tarix Pharmaceuticals","startDate":"2013-12","conditions":"Hematologic Malignancies","enrollment":""},{"nctId":"NCT01882387","phase":"PHASE2","title":"Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"Tarix Pharmaceuticals","startDate":"2013-12","conditions":"Hematologic Malignancies","enrollment":""},{"nctId":"NCT00710372","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2008-06","conditions":"Mild Essential Hypertension, Moderate Essential Hypertension","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Angiotensin II Injection","genericName":"Angiotensin II Injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Angiotensin II is a vasoactive peptide that binds to angiotensin II receptors to increase blood pressure and restore vascular tone in patients with hypotension. Used for Distributive shock (septic shock) with hypotension refractory to catecholamines, Severe hypotension in critically ill patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}